- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Mota Ventures Forms Research and Development Partnership with Leading Colombian University & Research Hospital
Mota Ventures is pleased to announce Ihuana S.A.S has entered into a research partnership with La Fundacion Universitaria de Ciencias de la Salud.
Mota Ventures Corp. (CSE:MOTA, FSE:1WZ:GR, OTC:PEMTF) (the “Company”) is pleased to announce that its wholly owned subsidiary Ihuana S.A.S (“Ihuana”) has entered into a research cooperation agreement (the “Agreement”) with La Fundacion Universitaria de Ciencias de la Salud (The University Foundation of Health Sciences) (the “University”) located in Bogota, Colombia. Pursuant to the Agreement, the parties intend to engage in research and formulation of medicinal products made with non-psychoactive cannabis and cannabis byproducts.
The University is a not-for-profit private educational and health care university founded in 1976. Between their two locations, including a Children’s Hospital in San Jose, the University has the necessary technology for highly specialized medical and surgical treatments including an automated clinical laboratory, diagnostic imaging, neurological sciences, internal medicine and outpatient care. Additionally, the foundation offers laboratories in biology, biochemistry, anatomy, physiology, genetics, immunology, histology, microbiology and clinical stimulation.
Ihuana and the University will cooperate in the development of scientific investigations related to the medical use of products made with cannabis. The research teams from both groups will work closely to design and execute studies, with the University providing the infrastructure and connections to different researchers and Ihuana supplying various resources, including testing materials. Cost of the research will be negotiated between the two parties for each individual research product and intellectual property from the study will be divided based on capital input from each side.
The University agrees to enable access and interaction with partner hospitals and research centers that will take part in clinical studies and trials and will allow access to institutional resources to finance research through existing relationships.
“This partnership gives us an immediate foothold in the medicinal market in Colombia. We are very fortunate to partner with one of the leading universities in South America. This will allow for rapid development of new products for the domestic and international markets,” stated Joel Shacker, CEO of the Company.
About Mota Ventures Corp.
Mota Ventures is seeking to become a vertically integrated global CBD brand. Its plan is to cultivate and extract CBD into high-quality value-added products from its Latin American operations and distribute it both domestically and internationally. Its existing operations in Colombia consist of a 2.5-hectare site that has optimal year-round growing conditions and access to all necessary infrastructure. Mota Ventures a seeking to become a vertically integrated, revenue-producing CBD company with operations in both Europe and North America. Mota is looking to establish sales channels and a distribution network internationally through the acquisition of the Sativida and First Class CBD brands. Low cost production, coupled with international, direct to customer sales channels will provide the foundation for the success of Mota Ventures.
About the University Foundation of Health Sciences
The University Foundation of Health Sciences is a modernized private educational and health care university founded in 1976. Between two locations, including a Children’s Hospital in San Jose, the University has the necessary technology for highly specialized medical and surgical treatments including an automated clinical laboratory, diagnostic imaging, neurological sciences, internal medicine and outpatient care. Additionally, the foundation offers laboratories in biology, biochemistry, anatomy, physiology, genetics, immunology, histology, microbiology and clinical stimulation.
ON BEHALF OF THE BOARD OF DIRECTORS
MOTA VENTURES CORP.
Joel Shacker
Chief Executive Officer
For further information, readers are encouraged to contact Joel Shacker, President & CEO at +604.423.4733 or by email at IR@motaventuresco.com or www.motaventuresco.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.
Cautionary Note Regarding Forward-Looking Statement
All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to research and development projects with the University, its plans to become a vertically integrated global CBD brand, its plans to cultivate and extract cannabis to produce CBD and high-quality value added CBD products in Latin America for distribution domestically and internationally and its plans to acquire revenue-producing CBD brands and operations in Europe and North America. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.